Peter Barrett Ph.D.

Background

Dr. Peter Barrett, Ph.D. is a Partner of Atlas Venture L.P. Dr. Barrett joined Atlas Venture in 2002 and is a part of the life sciences group. He focuses on investments in therapeutics and medical technologies that significantly change the medical management of patient. At Atlas, Dr. Barrett has been involved in the creation of several novel therapeutic and drug discovery platform companies. In addition, he incubated Stromedix in Atlas’ offices and was actively involved ... in building both Alnylam and Momenta Pharmaceuticals. He leverages his background in corporate business development to provide strategic and negotiating guidance to his portfolio; he was instrumental in the sales of Stromedix to Biogen and Novamed to SciClone Pharmaceuticals. He leverages his background in corporate business development to provide strategic and negotiating guidance to his portfolio. He serves as Adjunct Professor at the Barnett Institute. He serves as the President of the Autism Consortium. He was the Co-founder of Celera Corporation and served as its Executive Vice President and Chief Business Officer. He helped launch Celera as a publicly traded entity in 1999. He served as Vice President of Corporate Planning and Business Development at Applera Corp. Dr. Barrett led Celera’s strategic alliances and acquisitions and participated in raising nearly $1 billion in capital for the company. He served at The Perkin-Elmer Corporation from 1980 to 1990 and served as its Vice President of Corporate Planning and Business Development and as an Executive Vice President of the Applied Biosystems Division. He expanded the life science business units through a series of licensing agreements, partnerships, and acquisitions including Applied Biosystems, Inc., Tropix, Molecular Informatics, PerSeptive Biosystems, and Genscope. He served as Executive Vice President of Applied Biosystems Division at Perkin-Elmer. He served as the Acting Chief Executive Officer of Zafgen. He held senior management positions at PerkinElmer, serving as Vice President of Corporate Planning and Business Development. During his tenure, he expanded the life science business units through a series of licensing agreements, partnerships, and acquisitions. He serves as the Chairman of Ivrea Pharmaceuticals, Inc.; Molecular Biometrics, Inc.; Harbour Antibodies BV. He has been the Chairman of Zafgen, Inc. since August 2006. He serves as the Chairman of Raze Therapeutics which he co-founded. He serves as the Vice Chairman of the Advisory Council of the Barnett Institute of Chemical and Biological Analysis at Northeastern University. Dr. Barrett has been Independent Director of PerkinElmer Inc. since February 1, 2012. He serves as a Director of Aureon Biosciences, Inc. He serves as a Director of Sirion Therapeutics, Inc. and Momenta Pharmaceuticals. He serves as a Director of Mnemosyne Pharmaceuticals, Inc., Aureon Laboratories, JenaValve Technology GmbH, Molecular Biometrics and InfaCare Pharmaceutical Corporation, Stromedix, Inc. He has been a Director of Vitae Pharmaceuticals, Inc. since May 2004. Dr. Barrett has been the Chairman of Synlogic, Inc. since July 22, 2014. He served as the Chairman of Momenta Pharmaceuticals Inc. from June 2005 to December 2008. He served as Chairman of the Board of the Analytical and Life Science System Association. He served as a Director of SciClone Pharmaceuticals, Inc., from April 2011 to June 27, 2013. He served as Lead Director of Archemix Corp. Dr. Barrett's served as a Director of HuBit Genomix Inc., Genecore, Roche Strategic Alliance, and Sciex Joint Venture. He served as a Director of Momenta Pharmaceuticals, Inc. from May 2005 to December 2008. He served as a Director of Alnylam Pharmaceuticals, Inc. from July 2002 to June 1, 2007. He served as a Director of Akela Pharma Inc. since December 2005. Dr. Barrrett served as a Director of Helicos BioSciences Corporation from 2003 to August 24, 2012. He holds a Ph.D. degree in Analytical Chemistry from Northeastern University, a B.Sc. degree in Chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and also completed Harvard Business School’s Management Development Program.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.